The Protocol Review and Monitoring System (PRMS) oversees and ensures the scientific merit and progress of all clinical studies at the Yale Cancer Center (YCC). The PRMS evaluation process occurs prior to submission to the Yale University institutional review board (known as the Human Investigation Committee or HIC) and is required for IRB approval. The PRMS process is complementary to the IRB review and does not overlap or duplicate the responsibilities of the IRB. There are two major committees of the PRMS that provide for clinical research review and oversight: the Clinical Research Steering Committee (SC), and the Protocol Review Committee (PRC). Although each Committee has a unique role, when combined these are aligned to ensure that research concepts and protocols move through the system in a timely fashion, receive high-quality peer review and monitoring, and that the research protocol is consistent with YCC clinical research priorities. Proposed protocols are initially discussed in disease teams and then presented to the SC where they are assessed for feasibility and consistency with overall YCC goals. After receiving SC approval the study then proceeds to the PRO for full scientific and biostatistical review, priority scoring and assessment of the data and safety monitoring plan. After approval the PRMS provides ongoing review to ensure adequate accrual, scientific progress and continued consistency with overall YCC goals. The SC conducts reviews of each disease team portfolio at six month intervals to assess progress, rates of accrual and continued consistency with the priorities of the YCC. The SC then makes recommendations for closure to the PRC if studies are not progressing towards the scientific objectives. The PRC has the authority to close studies. In Fiscal Year 2012, a total of 94 new protocols were evaluated by the PRMS for merit, and 201 protocols were monitored for scientific progress.

Public Health Relevance

Promotes high quality scientific investigations consistent with the overall mission of the YCC that can be completed in a timely manner in order to improve treatments for cancer patients. The PRMS serves as a centralized review system to encourage creativity, collaborations, and well designed studies that will advance understanding and knowledge of cancer etiology, treatments and support services for patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-34
Application #
8558329
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-01
Project End
2018-07-31
Budget Start
2013-09-09
Budget End
2014-07-31
Support Year
34
Fiscal Year
2013
Total Cost
$84,945
Indirect Cost
$33,927
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Yanez, Diana A; Lacher, Richard K; Vidyarthi, Aurobind et al. (2017) The role of macrophages in skin homeostasis. Pflugers Arch 469:455-463
Langdon, Casey G; Platt, James T; Means, Robert E et al. (2017) Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Mol Cancer Ther 16:1041-1053
Kim, Bong-Sung; Ott, Veronica; Boecker, Arne Hendrick et al. (2017) The Effect of Antiseptics on Adipose-Derived Stem Cells. Plast Reconstr Surg 139:625-637
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2017) Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res :
Toki, Maria I; Cecchi, Fabiola; Hembrough, Todd et al. (2017) Proof of the quantitative potential of immunofluorescence by mass spectrometry. Lab Invest 97:329-334
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Wang, Simeng; Yang, Xiaoyong (2017) Inter-organ regulation of adipose tissue browning. Cell Mol Life Sci 74:1765-1776
Acharya, Dhiraj; Wang, Penghua; Paul, Amber M et al. (2017) Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance. J Virol 91:
Swartz, Kelsey L; Wood, Scott N; Murthy, Tushar et al. (2017) E2F-2 Promotes Nuclear Condensation and Enucleation of Terminally Differentiated Erythroblasts. Mol Cell Biol 37:
Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania et al. (2017) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecol Oncol 146:179-186

Showing the most recent 10 out of 631 publications